On Mar. 4, 2021, Luminex announced that it had received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG Respiratory Pathogen Panel that included the SARS-CoV-2 virus for high-throughput respiratory testing.

The new test was a combination of the company’s original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, and SARS-CoV-2.